May 8, 2020 / 2:44 PM / 18 days ago

BRIEF-Sorrento Says Co, Mount Sinai Health System To Jointly Develop COVI-SHIELD Antibody Therapy Targeting Covid-19

May 8 (Reuters) - Sorrento Therapeutics:

* SORRENTO SAYS CO, MOUNT SINAI HEALTH SYSTEM TO JOINTLY DEVELOP COVI-SHIELD ANTIBODY THERAPY TARGETING COVID-19

* SORRENTO - EXPECTS TO COMMENCE PHASE 1 TRIALS OF ANTIBODY THERAPY TO POTENTIALLY TREAT COVID-19 IN Q3 2020

* SORRENTO - IF APPROVED, ANTICIPATED THAT COVI-SHIELD WILL BE OFFERED FOR ADMINISTRATION AS A PROPHYLACTIC FOR THOSE RETURNING TO WORK

* SORRENTO - AIMS TO GENERATE ANTIBODY PRODUCTS THAT POTENTIALLY BLOCK, NEUTRALIZE ACTIVITY OF CORONAVIRUS

* SORRENTO - ANTIBODY THERAPY TARGETING COVID-19 IS DESIGNED TO BE RESISTANT TO FUTURE VIRUS MUTATIONS

* SORRENTO - IF APPROVED, ANTICIPATED THAT COVI-SHIELD WILL BE OFFERED AS A THERAPEUTIC TO THOSE EXPOSED TO SARS-COV-2 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below